Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · BROOKS

BROOKS LABS

HealthcarePharmaceuticals & Biotechnology₹197 cr market cap
₹67.30 ▲ +0.51% today As of 19 Nov 2026
52-week low ₹37.1152-week high ₹109.82

-39.0% from the 52-week high · +80.4% above the low

Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The firm has manufacturing plants at Baddi, Himachal Pradesh. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.

The short version. BROOKS LABS reported revenue of ₹19 crore for Sep 2026, down 17.4% from a year earlier. Net profit was ₹68 crore (up 750.0% year on year). Return on equity was 20.0% in Mar 2026. Promoter holding was 52.62% in Sep 2026, down 6.44 points over 8 quarters.

1 · The price

How has the stock traded?

BROOKS LABS trades 39.0% below its 52-week high and 80.4% above its 52-week low.

Change over period: —

1M+2.9%
3M+13.3%
6M+35.2%
1Y-36.0%

2 · The business

Is it growing?

Sales, year on year-17.4%

Sep 2026 revenue of ₹19 cr.

Profit, year on year+750.0%

Sep 2026 net profit of ₹68 cr.

Net margin351.3%

317.3 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1923201723262321
Net profit68-215810-1-2
Net margin %351.3-7.87.433.234.037.6-6.3-10.4
EPS (₹)22.95-0.610.511.872.713.25-0.49-0.81

Annual

FY2026FY2025FY2024FY2023FY2022FY2021
Revenue868379639177
Net profit25-10-20-21-16-19
Net margin %28.6-12.1-24.6-33.1-17.8-25.1
EPS (₹)8.34-3.38-7.46-7.96-6.17-7.38

3 · The quality

How well does it turn capital into profit?

Return on equity was 20.0% in Mar 2026; debt to equity is 0.06.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %20.0-10.2-29.9-28.3
Return on capital %5.34.23.6-43.9
EBITDA margin %9.57.05.2-41.9
Net margin %28.2-11.9-24.4-33.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR11.1%2.2%
Profit CAGR——
Debt to equity0.06
Interest cover8.0x
Current ratio1.72
P/E ratio3.0

4 · The owners

Who holds it, and are they adding?

Promoter holding52.62%

Down 6.44 pts over 8 quarters.

Foreign institutions0.04%

Up 0.03 pts over 8 quarters.

Domestic institutions10.5%

Up 6.64 pts over 8 quarters.

Mutual fund schemes1

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter59.0652.6252.6252.6252.6252.6252.6252.62-6.44
FII0.010.0500.010.090.1700.04+0.03
DII3.8610.3810.3810.3810.3810.3810.3810.5+6.64
Public37.0836.9537.037.036.9136.8437.036.84-0.24

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for BROOKS LABS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about BROOKS LABS

What is the BROOKS LABS share price?

BROOKS LABS (BROOKS) last closed at ₹67.30, up 0.51% on the day. Its 52-week range is ₹37.11 to ₹109.82.

What is the market cap of BROOKS LABS?

BROOKS LABS has a market capitalisation of about ₹197 crore. Its price-to-earnings ratio is 3.0.

How are BROOKS LABS's latest results?

BROOKS LABS reported revenue of ₹19 crore for Sep 2026, down 17.4% from a year earlier. Net profit was ₹68 crore (up 750.0% year on year). Return on equity was 20.0% in Mar 2026. Promoter holding was 52.62% in Sep 2026, down 6.44 points over 8 quarters.

Who owns BROOKS LABS?

As of Sep 2026, shareholding was: Promoter 52.62%, FII 0.04%, DII 10.5%, Public 36.84%.

How many mutual funds hold BROOKS LABS?

1 mutual fund schemes held BROOKS LABS in October 2026. That compares with 1 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 28 Jul 2023 · Rights issue 1:16
  • 11 Feb 2020 · Rights issue 9:20

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.